Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MCRB

Seres Therapeutics Inc

Dec 13 • 04:00PM ET

0.8786

Dollar change +0.0181
Percentage change 2.10	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP FATE NTLA BPMC SANA EDIT BLUE ADPT XBIO CLRB

| Held by: VTI VXF SCHA VHT SCHB QQQS BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.19	Insider Own	26.90%	Shs Outstand	170.20M	Perf Week	6.72%
Market Cap	153.17M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	-0.13%	Shs Float	124.81M	Perf Month	48.86%
Income	-172.18M	PEG	-	EPS next Q	-0.20	Inst Own	23.58%	Short Float	13.93%	Perf Quarter	-13.86%
Sales	0.06M	P/S	2552.76	EPS this Y	86.61%	Inst Trans	-12.91%	Short Ratio	4.69	Perf Half Y	24.04%
Book/sh	0.14	P/B	6.25	EPS next Y	-177.75%	ROA	-60.50%	Short Interest	17.38M	Perf Year	-16.32%
Cash/sh	0.38	P/C	2.29	EPS next 5Y	-	ROE	-3758.21%	52W Range	0.54 - 2.05	Perf YTD	-37.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.22%	ROI	-157.70%	52W High	-57.14%	Beta	2.09
Dividend TTM	-	Quick Ratio	1.12	Sales past 5Y	386.36%	Gross Margin	-13081.25%	52W Low	62.70%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.12	EPS Y/Y TTM	-5.95%	Oper. Margin	-225450.00%	RSI (14)	54.59	Volatility	11.86% 12.97%
Employees	233	Debt/Eq	3.91	Sales Y/Y TTM	-99.95%	Profit Margin	-269034.37%	Recom	2.25	Target Price	3.31
Option/Short	Yes / Yes	LT Debt/Eq	3.56	EPS Q/Q	-1.74%	Payout	-	Rel Volume	0.57	Prev Close	0.86
Sales Surprise	-100.00%	EPS Surprise	848.39%	Sales Q/Q	-100.00%	Earnings	Nov 13 BMO	Avg Volume	3.70M	Price	0.88
SMA20	6.64%	SMA50	11.40%	SMA200	-0.72%	Trades		Volume	2,121,322	Change	2.10%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform	$12
Apr-21-23	Initiated	JP Morgan	Neutral	$7
Jul-23-21	Downgrade	Goldman	Neutral → Sell	$24 → $7
May-18-21	Resumed	Goldman	Neutral	$24
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$30
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$32.50 → $27.50
Aug-18-20	Initiated	Piper Sandler	Overweight	$40
Aug-11-20	Upgrade	Jefferies	Hold → Buy	$4 → $29
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$8 → $41
Apr-30-19	Initiated	Jefferies	Hold	$7
Oct-22-18	Initiated	Chardan Capital Markets	Buy	$15
Oct-13-17	Initiated	Oppenheimer	Outperform	$19
Aug-04-17	Reiterated	H.C. Wainwright	Buy	$15 → $19
Feb-01-17	Reiterated	FBR & Co.	Outperform	$23 → $18
Aug-12-16	Reiterated	FBR Capital	Outperform	$43 → $23
Aug-01-16	Reiterated	H.C. Wainwright	Buy	$50 → $15
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Jul-29-16	Resumed	H.C. Wainwright	Buy	$50
Mar-30-16	Initiated	FBR Capital	Outperform	$40

Show Previous Ratings

Dec-10-24 05:43AM	Seres SER-155 gains breakthrough status for BSIs reduction (Pharmaceutical Technology) +9.20%
Dec-09-24 07:00AM	FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire)
Nov-22-24 07:00AM	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference (GlobeNewswire) +5.03%
Nov-14-24 02:08AM	Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... (GuruFocus.com)
Nov-13-24 07:23AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -11.10%
07:00AM	Loading…
07:00AM	Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:00AM	Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 (GlobeNewswire) -6.98%
Sep-30-24 05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Societe des Produits Nestle S.A (GlobeNewswire)
05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Soci t des Produits Nestl S.A (GlobeNewswire)
Sep-27-24 03:26PM	Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestle (Business Wire) +10.44%
Sep-26-24 04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestle Health Science; Sale Expected to Close on September 30 (GlobeNewswire) -9.10%
04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science; Sale Expected to Close on September 30 (GlobeNewswire)
Sep-13-24 07:00AM	Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference (GlobeNewswire)
Sep-12-24 07:00AM	Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire) -8.57%
Sep-04-24 09:35AM	After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) (Zacks)
09:55AM	Loading…
Aug-15-24 09:55AM	Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now (Zacks)
Aug-14-24 03:09AM	Q2 2024 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.07%
Aug-13-24 07:15AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.97%
07:00AM	Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-24 07:00AM	Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024 (GlobeNewswire) -21.09%
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestle Health Science (GlobeNewswire)
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestl Health Science (GlobeNewswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire) -6.18%
Jun-07-24 04:00PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -28.03% +20.54%
Jun-06-24 07:05AM	Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle (BioPharma Dive) -25.17%
07:00AM	Nestl Health Science agrees to acquire global rights to VOWST, product it launched in June 2023 (PR Newswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestle Health Science (GlobeNewswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestl Health Science (GlobeNewswire)
May-13-24 12:18PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.38%
May-09-24 11:06AM	Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating (MT Newswires) +37.44%
07:00AM	Loading…
07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
06:30AM	Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating (MT Newswires)
03:11AM	Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
May-08-24 11:54AM	MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -32.49%
08:42AM	Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates (GuruFocus.com)
07:25AM	Seres Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-06-24 04:01PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.72%
09:30AM	Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 (Business Wire)
Apr-09-24 07:00AM	Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT (Business Wire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire) +6.34%
07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey)
08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-07-24 11:48AM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 02:17AM	Q4 2023 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 09:51AM	MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.02%
07:32AM	Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023 (GuruFocus.com)
07:00AM	Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-28-24 07:00AM	Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 (Business Wire)
Feb-27-24 07:00AM	Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference (Business Wire) +6.54%
Feb-26-24 07:00AM	Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz (Business Wire)
Jan-17-24 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire) -8.33%
07:00AM	Seres Therapeutics Announces VOWST Commercial Launch Update and US FDA Fast Track Designation for SER-155 (Business Wire)
Jan-08-24 06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire) +11.43%
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-04-24 04:00PM	Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +5.26%
Dec-07-23 07:46PM	Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023 (Business Wire)
Nov-28-23 09:18AM	Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET (Business Wire)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire) +7.72%
Nov-05-23 02:22PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:47AM	Seres Therapeutics Inc (MCRB) Announces Q3 2023 Financial Results and Strategic Restructuring (GuruFocus.com) -35.25%
07:32AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST Net Sales of $7.6 Million (Business Wire)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire) -5.88%
Oct-30-23 05:30PM	Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST (Business Wire) +5.07% +5.52%
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-12-23 07:00AM	Seres Therapeutics to Highlight VOWST Data at IDWeek (Business Wire) -12.72%
Oct-06-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.68%
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire) -9.66%
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-08-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-07-23 10:00AM	Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-09-23 06:27AM	Investors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Tunnel (Simply Wall St.) -6.06%
Aug-08-23 08:25AM	Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates (Zacks) -6.94%
07:19AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Aug-04-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 07:00AM	Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
07:00AM	Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023 (Business Wire)
Jul-14-23 04:01PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.09%
Jul-07-23 10:17AM	Seres Therapeutics (NASDAQ:MCRB) shareholders have endured a 47% loss from investing in the stock five years ago (Simply Wall St.)
Jun-21-23 09:00AM	Seres Therapeutics Named to TIME100 Most Influential Companies List (Business Wire) +6.52%
Jun-17-23 03:45PM	Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023 (Business Wire)
Jun-09-23 07:00AM	Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference (Business Wire)
07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-23 07:00AM	Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection (Business Wire)
Jun-02-23 07:00AM	Seres Therapeutics to Present at Jefferies Healthcare Conference (Business Wire)
May-30-23 04:00PM	Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST (Business Wire) +5.32%
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire)
May-10-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 08:15AM	Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Seres Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:00AM	Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome (Business Wire)

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DesRosier Thomas	Chief Legal Officer and EVP	Nov 18 '24	Sale	0.54	878	475	135,192	Nov 19 04:21 PM
von Moltke Lisa	See Remarks	Nov 18 '24	Sale	0.54	977	528	32,415	Nov 19 04:20 PM
Shaff Eric D.	CEO and President	Nov 18 '24	Sale	0.54	2,505	1,355	170,389	Nov 19 04:15 PM
Young Teresa L.	See Remarks	Nov 18 '24	Sale	0.54	735	398	90,404	Nov 19 04:15 PM
Henn Matthew R.	See Remarks	Nov 18 '24	Sale	0.54	927	501	77,770	Nov 19 04:15 PM
von Moltke Lisa	See Remarks	Oct 27 '24	Option Exercise	0.00	13,744	0	34,757	Oct 29 06:33 PM
von Moltke Lisa	See Remarks	Oct 28 '24	Sale	0.69	4,334	2,991	30,423	Oct 29 06:33 PM
Henn Matthew R.	See Remarks	Oct 27 '24	Option Exercise	0.00	12,622	0	79,869	Oct 29 06:27 PM
Henn Matthew R.	See Remarks	Oct 28 '24	Sale	0.69	3,984	2,749	75,885	Oct 29 06:27 PM
DesRosier Thomas	Chief Legal Officer and EVP	Oct 27 '24	Option Exercise	0.00	13,500	0	137,673	Oct 29 06:26 PM
DesRosier Thomas	Chief Legal Officer and EVP	Oct 28 '24	Sale	0.69	4,259	2,939	133,414	Oct 29 06:26 PM
Shaff Eric D.	CEO and President	Oct 27 '24	Option Exercise	0.00	27,837	0	173,830	Oct 29 06:24 PM
Shaff Eric D.	CEO and President	Oct 28 '24	Sale	0.69	8,748	6,037	165,082	Oct 29 06:24 PM
Young Teresa L.	See Remarks	Oct 27 '24	Option Exercise	0.00	11,360	0	91,466	Oct 29 06:23 PM
Young Teresa L.	See Remarks	Oct 28 '24	Sale	0.69	2,983	2,059	88,483	Oct 29 06:23 PM
DesRosier Thomas	Chief Legal Officer and EVP	Aug 16 '24	Sale	0.84	873	733	124,173	Aug 19 05:48 PM
von Moltke Lisa	See Remarks	Aug 16 '24	Sale	0.84	973	817	21,013	Aug 19 05:45 PM
Henn Matthew R.	See Remarks	Aug 16 '24	Sale	0.84	923	775	67,247	Aug 19 05:42 PM
Shaff Eric D.	CEO and President	Aug 16 '24	Sale	0.84	2,518	2,115	145,993	Aug 19 05:38 PM
Young Teresa L.	See Remarks	Aug 16 '24	Sale	0.84	728	612	80,106	Aug 19 05:36 PM
Ege David S.	See Remarks	Aug 16 '24	Sale	0.84	1,128	948	77,575	Aug 19 05:29 PM
Young Teresa L.	See Remarks	Aug 05 '24	Sale	1.08	24,480	26,534	78,178	Aug 06 04:15 PM
von Moltke Lisa	See Remarks	May 15 '24	Sale	0.94	939	883	19,017	May 17 08:23 PM
Shaff Eric D.	CEO and President	May 15 '24	Sale	0.94	2,435	2,289	140,698	May 17 08:18 PM
Young Teresa L.	See Remarks	May 15 '24	Sale	0.94	703	661	17,658	May 17 08:18 PM
Henn Matthew R.	See Remarks	May 15 '24	Sale	0.94	891	838	65,357	May 17 08:17 PM
Ege David S.	See Remarks	May 15 '24	Sale	0.94	1,090	1,025	75,734	May 17 08:16 PM
DesRosier Thomas	Chief Legal Officer and EVP	May 15 '24	Sale	0.94	843	792	122,390	May 17 08:14 PM
DesRosier Thomas	Chief Legal Officer and EVP	Feb 16 '24	Sale	1.08	3,939	4,254	120,577	Feb 16 09:48 PM
Shaff Eric D.	CEO and President	Feb 16 '24	Sale	1.08	11,549	12,473	135,321	Feb 16 09:42 PM
Henn Matthew R.	See Remarks	Feb 16 '24	Sale	1.08	4,170	4,504	63,436	Feb 16 09:31 PM
Young Teresa L.	See Remarks	Feb 16 '24	Sale	1.08	3,374	3,644	15,705	Feb 16 09:29 PM
von Moltke Lisa	See Remarks	Feb 16 '24	Sale	1.08	4,400	4,752	16,988	Feb 16 09:21 PM
Ege David S.	See Remarks	Feb 16 '24	Sale	1.08	5,010	5,411	73,856	Feb 16 09:15 PM
Arkowitz David	Chief Financial Officer	Feb 16 '24	Sale	1.08	3,939	4,254	182,442	Feb 16 09:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MCRB

Seres Therapeutics Inc

Upgrade your FINVIZ experience